Skip to main content
SpringerLink
Log in
Book cover

The Biology and Prevention of Aerodigestive Tract Cancers pp 129–136Cite as

Chemoprevention of Barrett’s Esophagus and Oral Leukoplakia

  • Chapter

  • 65 Accesses

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 320))

Abstract

Studies of premalignant lesions constitute an important approach to devising strategies for preventing cancer. Cancer develops through a series of sequential steps involving initiation, promotion, and progression to invasive malignancy. However, many of the early steps in this pathway are reflected as changes at the subcellular level only and, therefore, cannot be identified phenotypically as clinical lesions. Premalignant lesions are often the first clinically recognizable lesions. that can be used to identify a tissue affected by carcinogens. Barrett’s esophagus and oral leukoplakia, for example, are considered premalignant lesions for esophageal adenoearcinoma and oral cancer, respectively. Lesions such as these characterize one of the better-defined, intermediate end points whose reversal or suppression can be studied to evaluate useful approaches for the overall chemoprevention of cancer.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barrett NR. Chronic peptic ulcer of the esophagus and “esophagitis.” Br J Surg 38:178–182, 1950.

    Article  Google Scholar 

  2. Sjogren RW, Johnson LF. Barrett’s esophagus: A review. Am J Med 74:313–321,1983.

    Article  PubMed  Google Scholar 

  3. Winters C, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF, Johnson DA, Cruess DF, Cotelingam JD, Gurney MS, Cattau EL. Barrett’s esophagus: A prevalent occult complication of gastroesophageal reflux disease. Gastroenterology 92:118–124, 1987.

    PubMed  Google Scholar 

  4. Cameron EL, Zinsmeister ER, Ballard DJ, Carney JE. Prevalence of columnar-lined (Barrett’s) esophagus: Comparison of population-based clinical and autopsy findings. Gastroenterology 99:918–922, 1990.

    PubMed  CAS  Google Scholar 

  5. Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: An acquired lesion with malignant predisposition. Report on 140 cases of Barrett’s esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg 70:826–835, 1975.

    PubMed  CAS  Google Scholar 

  6. Cameron AJ, Ott BJ, Payne WP. The incidence of adenocarcinoma in columnar-lined (Barrett’s) esophagus. N Engl J Med 313:857–859, 1985.

    Article  PubMed  CAS  Google Scholar 

  7. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 243:C212–C221,1982.

    PubMed  CAS  Google Scholar 

  8. Verma AK, Boutwell RK. Inhibition of carcinogenesis by inhibitors of putrescine biosynthesis. In McCann PP, Pegg AE, Sjoerdsma A (eds): Inhibition of Polyamine Metabolism. Orlando, FL: Academic Press, 1987, pp. 249–258.

    Google Scholar 

  9. Luk GD, Baylin SB. ODC as a biologic marker in familial colonic polyposis. N Engl J Med 311:80–83,1984.

    Article  PubMed  CAS  Google Scholar 

  10. Rozhin J, Wilson PS, Bull AW, Nigro ND. Omithine dccarboxylase activity in the rat and human colon. Cancer Res 44:3326–3330, 1984.

    Google Scholar 

  11. Lamurglia GM, Lacaine F, Malt RA. High ornithine decarboxylase activity and polyamine levels in human colorectal neoplasia. Ann Surg 204:89–93, 1986.

    Article  Google Scholar 

  12. Sloan D, Garewal HS, Hixson L, Sampliner RE, Fennerty MB. ODC activity in colonic neoplasms. Proceedings of the American Association for Cancer Research, in press.

    Google Scholar 

  13. Garewal HS, Sampliner R, Kogan F, Smith W, Gerner E, Alberts D, Kendall D. Ornithine decarboxylase levels. in Barrett’s esophagus: A premalignant lesion for adenocarcinoma. Proceedings of the American Society of Clinical Oncology 5:18, 1986.

    Google Scholar 

  14. Garewal HS, Sampliner R, Gemer E, Steinbronn K, Alberts D, Kendall D. Omithine decarboxylase activity in Barrett’s esophagus: A potential marker for dysplasia. Gastroenterology 94:819–821,1988.

    CAS  Google Scholar 

  15. Garewal HS, Gemer EW, Sampl iner R, Roe D. Ornithine dccarboxylase and polyamine levels in columnar upper gastrointestinal mucosae in patients at risk for adenocarcinoma. Cancer Res 48:3288–3291, 1988.

    PubMed  CAS  Google Scholar 

  16. Garewal HS, Sampliner RE, Fennerty MB. Flow cytometry in Barrett’s esophagus. What have we learned so far? Dig Dis Sci, in press.

    Google Scholar 

  17. Reid BF, Haggitt RC, Rubin CE, Rabinovitch PS. Barrett’s esophagus: Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 93:1–11,1987.

    PubMed  CAS  Google Scholar 

  18. Fennerty MB, Way D, Sampliner R, Riddell R, Sloan D, Garewal HS. Discordance between flow cytometry and dysplasia in patients with Barrett’s esophagus. Gastroenterology 94:A143, 1988.

    Google Scholar 

  19. McKinley MK, Budman DR, Grueneberg D, Bronzo RL, Weissman GS, Kahn E. DNA content in Barrett’s esophagus and esophageal malignancy. Am J Gastroenterol 82:1012–1015, 1987.

    PubMed  CAS  Google Scholar 

  20. Garewal HS, Leibovitz A, Sampl R, Prabhala R, Trent J, Korc M, Sloan D. Tissue culture and characterization of epithelial cells derived from Barrett’s esophagus: A premalignant lesion. Gastroenterology 94:A143, 1988.

    Google Scholar 

  21. Garewal HS, Sampliner RE, Liu Y, Trent JM. Chromosomal rearrangements in Barrett’s esophagus, a premalignant lesion of esophageal adenocarcinoma. Cancer Genet Cytogenet 42:281–296, 1989.

    Article  PubMed  CAS  Google Scholar 

  22. Garewal HS, Prabhala R, Sampl iner R, Sloan D. Effect of potcn tial di ITerentiating agents on the growth of Barrett’s esophagus-derived epithelial cell cultures. Clin Res 36:131A, 1988.

    Google Scholar 

  23. Sampliner RE, Garewal HS. Phase II trial of 13-cis retinoic acid (isotretinoin) in Barrett’s esophagus. Gastroenterology 94:A396, 1988.

    Google Scholar 

  24. Fennerty MB, Sampliner RE, Garewal HS. Esophageal ulceration associated with 13-cis-retinoic acid therapy in patients with Barrett’s esophagus. Gastrointest Endosc 35:442–443, 1989.

    Article  PubMed  CAS  Google Scholar 

  25. Silverman S, Shillitoc EJ. Etiology and predisposing factors. In Silverman S (ed): Oral Cancer, 2nd ed. Atlanta: American Cancer Society, 1985, pp. 7–36.

    Google Scholar 

  26. Parkin SM, Lanra E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers. Int J Cancer 41:184–197, 1988.

    Article  PubMed  CAS  Google Scholar 

  27. Baden E. Tabacet cancers de la region oropharyngee et des bronches. Donnees actuelles. Revue de Medecine de Toulouse 14:549–560, 1978.

    Google Scholar 

  28. Dunham LJ. A geographic study of a relationship between oral cancer and plants. Cancer Res 28:2369–2371, 1968.

    PubMed  CAS  Google Scholar 

  29. U.S. Department of Health and Human Services: The Health ConsequencesofSmoking& Cancer, 1982.Areport of the Surgeon General. DHS Publication No. 82–5017, 1982.

    Google Scholar 

  30. Ziegler RG. A review of epidemiologic evidence that carotenoids reduce the risk of cancer. J Nutr 119:116–122, 1989.

    PubMed  CAS  Google Scholar 

  31. Burge-Bottenblcy A, Shklar G. Retardation of experimental oral cancer development by retinyl acetate. Nutr Cancer 5:121–129,1983.

    Article  Google Scholar 

  32. Schwartz J, Suda D, Light G. Beta-carotene is associated with the regression of hamster buccal pouch carcinoma and induction of tumor necrosis factor in macrophages. Biochem Biophys Res Commun 136:1130–1135,1986.

    Article  PubMed  CAS  Google Scholar 

  33. Shklar G, Schwartz J, Trickier D, Reid S. Regression of experimental cancer by oral administration of combined alpha-tocopherol and beta-carotene. Nutr Cancer 12:321–325, 1989.

    Article  PubMed  CAS  Google Scholar 

  34. Stich HF, Rosin MP, Homby AP, Mathew B. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. IntJ Cancer 42:195–199,1988.

    Article  CAS  Google Scholar 

  35. Karp DD, Guralnick E, G uid ice LA, Meuser C, Vaughan CW, Faling LJ, Levine JD, Hong WK. Multiple primary cancers: A prevalent and increasing problem. Proceedings of the American Society of Clinical Oncology 4:13, 1985.

    Google Scholar 

  36. Kotwall C, Razack MS, Sako K, Rao U. Multiple primary cancers in squamous cell cancers of the head and neck. J Surg Oncol 40:97–99, 1990.

    Article  Google Scholar 

  37. McGuirt WF, Mathew B, Kaufman JA. Multiple simultaneous tumors in patients with head and neck cancer. Cancer 50:1195–1199, 1982.

    Article  PubMed  CAS  Google Scholar 

  38. Wong F, Epstein J, Millner A. Treatment of oral leukoplakia with topical bleomycin. Cancer 64:361–365, 1989.

    Article  PubMed  CAS  Google Scholar 

  39. Koch HF. Biochemical treatment of precancerous oral lesions: The effectiveness of various analogues of retinoic acid. J Oral Surg 6:59–63, 1978.

    CAS  Google Scholar 

  40. : Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, Fofonoff S, Byers R, Atkinson EN, Vaughan C, Toth BB, Kramer A, Dimery IW, Skipper P, Strong S. 13-Cis retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501–1505, 1986.

    Article  PubMed  CAS  Google Scholar 

  41. Stich HF, Homby AP, Mathew B, Sankaranarayanan R, Nair MK. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 40:93–101, 1988.

    Article  PubMed  CAS  Google Scholar 

  42. Garewal HS, Meyskens FL, Killen D, Reeves D, Kiersch TA, Elletson H, Strosberg A, King D, Steinbronn K. Response of oral leukoplakia to beta-carotene. J Clin Oncol 8:1715–1720, 1990.

    PubMed  CAS  Google Scholar 

  43. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H, MacDonald W, Owen D. Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Human Pathol 19:166–178,1988.

    Article  CAS  Google Scholar 

  44. Crissman JD.Thepathologyofincipientneoplasia.In Henson ED, Albores-Saavedra J(eds):Upper Aerodigestive Tract. Philadelphia: WB Saunders, 1986, pp. 39–55.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Veterans Affairs Medical Center, Cancer Prevention and Control University of Arizona Cancer Center, Tucson, Arizona, USA

    Harinder S. Garewal

Authors
  1. Harinder S. Garewal
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA

    Guy R. Newell  & Waun Ki Hong  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Science+Business Media New York

About this chapter

Cite this chapter

Garewal, H.S. (1992). Chemoprevention of Barrett’s Esophagus and Oral Leukoplakia. In: Newell, G.R., Hong, W.K. (eds) The Biology and Prevention of Aerodigestive Tract Cancers. Advances in Experimental Medicine and Biology, vol 320. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3468-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3468-6_17

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6536-5

  • Online ISBN: 978-1-4615-3468-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation